James R. Lisbakken

Corporate Collaborations and License Agreements

• Represented ZymoGenetics in its corporate collaboration and license with Bristol Myers with Bristol-Myers Squibb for the development and commercialization of interferon lambda under which it could receive milestone payments in excess of one billion dollars.
• Represented clients in numerous corporate collaborations and license agreements with such companies as Glaxo, Eli Lilly, Bristol-Myers Squibb, MedImmune, Teva, Serono, Novo Nordisk, Abbott, Bayer, Kissei and Kirin

Research Institutions License Agreements

Represented clients in license agreements or sponsored research agreements with research institutions such as University of Washington, Fred Hutchinson Cancer Research Center, MIT, University of Texas Southwestern, and Mayo Clinic.

Joint Venture Agreements

Represented ICOS Corporation in its major joint venture and related agreements with Eli Lilly for the development and commercialization of the ICOS compound known as Cialis.

Outside General Counsel and Board Advisor

Acted as outside general counsel and board advisor to seven public life sciences companies.

Common Stock Offering

Represented ICOS Corporation, ZymoGenetics, Eden and other companies in their initial public offering and subsequent offerings of common stock.

Venture Equity, Debt, Sales of Royalty Streams

Represented ZymoGenetics and other clients in receiving financing in the form of venture equity, debt, sales of royalty streams and R&D partnerships.

Acquisitions

Represented Darwin Molecular, Ostex, Procyte, Alcide and others in connection with their acquisitions by larger companies.